EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSCJAG00000008767
Gene Symbol: SIGMAR1
5 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sirtuin 1

Ensembl ID : ENSCJAG00000019318
Gene Symbol: SIRT1
5 Cross references
159 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSCJAG00000010304
Gene Symbol: SMO
5 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSCJAG00000000689
Gene Symbol: SCNN1A
3 Cross references
153 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSCJAG00000020597
Gene Symbol: SCNN1B
3 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSCJAG00000020591
Gene Symbol: SCNN1G
5 Cross references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSCJAG00000006343
Gene Symbol: SCN1A
5 Cross references
140 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSCJAG00000031394
Gene Symbol: SCN10A
5 Cross references
302 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSCJAG00000009856
Gene Symbol: SCN11A
3 Cross references
96 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSCJAG00000006141
Gene Symbol: SCN2A
5 Cross references
130 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSCJAG00000006101
Gene Symbol: SCN3A
3 Cross references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSCJAG00000019443
Gene Symbol: SCN4A
5 Cross references
192 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).